Market Research Blog

The global Liquid Biopsy Market is expected to generate lucrative growth opportunities during the forecast period, with a total CAGR of 13.49% from 2022 to 2032. The global market is expected to be valued at US$ 1.146 billion in 2022 and to exceed US$ 4.126 billion in 2032. The rising cancer incidence and low treatment rates are driving the growth of the liquid biopsy market.

A liquid biopsy is known to be a non-invasive procedure as compared to surgical biopsies which aid in discovering a tumor with the help of a simple blood sample. Traces of cancer’s DNA in the blood can help in giving clues about which treatments are most likely to work for that patient. Liquid biopsies are commonly used to diagnose non-small cell lung cancer (NSCLC) and screening or a companion diagnostic for numerous other types of cancers such as gastrointestinal, colorectal, breast, prostate, and ovarian cancer.

The Cost-effectiveness and high efficacy of liquid biopsy over several other diagnostic tests are chief factors responsible for market growth. Fast-track approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for non-invasive cancer diagnosis tests will continue creating growth opportunities.

Request a Sample of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1396

Key Takeaways

• For decades, cancer has been constantly affecting humanity and the numbers continue to surge even with the emergence of better treatment and care. According to the reports by the World Health Organization (WHO), In 2020 it reported around 10 million deaths caused due to cancer. This staggering rise in number emphasizes the need for accurate and convenient cancer diagnostic systems for early detection.
• Governments in several high cancer-burden nations have made a pledge to assist cancer research by offering them adequate funds that can aid in improved outcomes. For instance, as per the National Institute of Health (NIH), the federal government has allocated US$ 119 Mn to National Cancer Institute for the fiscal year 2021.
• The India-UK Cancer Research Initiative in 2018, focused on improved and affordable approaches to cancer diagnosis and treatment. This initiative received investments valued at £5 Mn from the Department of Biotechnology (DBT), Ministry of Science & Technology, India, and Cancer Research UK (CRUK) each over a 5-year program.
• The government-led initiatives are expected to further promote cancer specialists all over the world in order to set research goals aimed at affordability, convenience, and optimal patient care in cancer treatments. Adequate funding will allow experts to develop research alliances to enable significant improvements against numerous cancer outcomes.

Inquire Before Buying Research Report: https://www.futuremarketinsights.com/ask-question/rep-gb-1396

Competitive Landscape

Key players in the liquid biopsy market are focusing on strategic collaborations with several end-users including hospitals, diagnostic centers, and cancer research institutes to strengthen their product offerings in the market. As per FMI analysis, tier-1 players will account for approximately 20-25% of the total sales.

Prominent industrial research funding along with product development agreements will offer proprietary benefits to manufacturers, helping them contribute to the development of accurate diagnosis methods for various cancers. In addition, gaining patents and government approvals for new technologies will remain one of the prominent growth strategies.

Key Companies Profiled:

• BIOCEPT, INC.
• Qiagen N.V.
• Trovagene, Inc
• Janssen Global Services, LLC
• MDxHealth SA
• Natera, Inc
• F. Hoffmann-La Roche Ltd
• Silicon Biosystems
• Pathway Genomics Corporation
• Sysmex Corporation

Buy This Report: https://www.futuremarketinsights.com/checkout/1396

More Insights into the Liquid Biopsy Market

According to the FMI analysis, the U.S. is anticipated to account for around 51% of the total market share in the global liquid biopsy market during the projection period. Growth prospects in the U.S. are attributed to surging government funding in order to support cancer research. The rising prevalence of cancer across the U.S. will generate high demand for highly accurate liquid biopsy services. Widespread technological developments including artificial intelligence, machine learning, and microchip-based liquid biopsy diagnostic services will lead to market expansion in the U.S.

The European liquid biopsy market is anticipated to surge significantly throughout the forecast period, attributed to the desirable healthcare policies along with high average per capita healthcare costs, which have produced a favorable climate in the United Kingdom for the adoption of modern cancer diagnostic technology.

The technological developments in the U.K. are expected to offer lucrative growth opportunities for players operating in the market, allowing them to benefit from technological advancements for better products and services. The U.K. will account for 24% of the market share, as estimated by FMI.

According to the FMI market survey, government initiatives in emerging economies like India are aimed at improving cancer awareness, research, and development and are anticipated to propel the growth of the liquid biopsy market in India, as per FMI’s market survey. As revealed by the National Cancer Registry, cancer incidence in men is estimated to reach 736,575 in 2025, with 806,218 cases to be recorded in women.

Key Segments Profiled in the Liquid Biopsy Industry Survey

Liquid Biopsy Market by Marker Type:

• CTCs (Circulating Tumour Cells)
• ctNA (Circulating tumor Nucleic Acids)
• Exosomes

Liquid Biopsy Market by Sample Type:

• Blood Liquid Biopsy
• Urine Liquid Biopsy
• Others (Plasma, Saliva, CSF) Liquid Biopsy

Liquid Biopsy Market by Application Type:

• Liquid Biopsy for Lung Cancer
• Liquid Biopsy for Gastrointestinal Cancer
• Liquid Biopsy for Prostate Cancer
• Liquid Biopsy for Breast Cancer
• Liquid Biopsy for Colorectal Cancer
• Liquid Biopsy for Leukemia

Explore Wide-ranging Coverage of FMI’s Healthcare Landscape:

• https://wineart24.com/read-blog/27235_parkinson-039-s-disease-market-is-projected-to-reach-a-market-size-of-us-17-12-b.html
• https://www.zedlike.com/blogs/56076/Parkinson-s-Disease-Market-is-projected-to-reach-a-market
• https://pastelink.net/kl5ikzqt

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

The global Companion Animal Specialty Drugs Market is anticipated to reach a valuation of US$ 56,828.56 Mn by 2032, with the market growing at an average CAGR of 4.21% from 2022 to 2032. Currently valued at US$ 37,624.67 Mn, the companion animal specialty drugs market is driven by the growing adoption of pets and the rising focus on animal health. The rise in the number of animal-derived products will further aid the growth of the companion animal specialty drugs market during the forecast period.

In the past few years, there’s been a rise in the number of pet owners as well as a growing awareness regarding the health of pet animals. In addition to this, technological advances in the administration of novel veterinary medicines will likely supplement the growth of the companion animal specialty drugs market through the assessment period. Again, the manufacture and approval of new drugs for the treatment of various animal ailments is stimulating the demand for companion animal specialty drugs. For instance, the growing occurrence of obesity amongst pet dogs and other companion animals contributes to a surge in the sales of anti-obesity drugs.

Request Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3984

Moreover, the significant rise in the number of animal healthcare and NGOs in the past couple of years is one of the major growth drivers of the companion animal specialty drugs market. Also, some pet diseases can even lead to serious effects on humans and need to be mitigated so as to deter infection. All of these factors contribute to the growth of the target market during the forecast period.

“Surge in the introduction of new veterinary medicines, rise in the number of pet owners, and growing awareness of animal health are furling the global growth of the companion animal specialty drugs market over the forecast period,” says an FMI analyst.  

Key Takeaways:

• Surging number of animal healthcare centers and NGOs will strengthen the market prospects.
• The companion animal specialty drugs market in the U.S. will account for 88% of the North American market share.
• Brazil’s companion animal specialty drugs market will be valued at US$ 426 Mn in 2022.
• The companion animal specialty drugs market in Germany will expand at a CAGR of 2.4%.
• Online veterinary pharmacies will grow at a CAGR of 6.8%.
• The parasiticide drug segment accounted for a market share of 32.2% in
• By product type, the vaccines segment will reach a value of US$ 2.89 Bn in 2022.
• By route of administration, the oral segment will account for a value of US$ 2.86 Bn in 2022.

Ask An Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-3984

Competitive Landscape 

Merck Animal Health (Merck & Co., Inc.), Boehringer Ingelheim International GmbH., Elanco Animal Health Incorporated, Virbac S.A., Biogenesis Bago SA, Piramal Group, Zoetis, NEOGEN Corporation., Vetoquinol S.A., and Ceva Santé Animale among others are some of the major players in the companion animal specialty drugs market profiled in the full version of the report.

Leading market players are focusing on developing innovative products with fewer side effects. These organizations are also adopting tactics like product releases, partnerships, collaborations, and other inorganic strategies to expand their consumer base.

More Insights into Companion Animal Specialty Drugs Market Report

In its latest report, FMI offers an unbiased analysis of the global companion animal specialty drugs market, providing historical data and forecast statistics for 2022 to 2032. To understand the global market potential, growth, and scope, the market is segmented on the basis of product type (antibiotics, anti-inflammatory drugs, parasiticides, heartworm, behavioral products, nutritional products, anti-obesity drugs, skin care products, vaccines), distribution channel (modern trade, online distribution, neighborhood stores, other retail formats), and region.

Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-3984

According to the latest FMI reports, based on segmentation, the vaccines segment is anticipated to dominate the market with a value of about US$ 2.89 Bn in 2022. On the basis of the distribution channel, online veterinary pharmacies will likely account for 37.8% of the market share while expanding at a CAGR of 6.8% during the forecast period.

Based on region, the companion animal specialty drugs market in the United States will likely account for 88% of the revenue share in North America. The growing adoption of pets coupled with many pet owners interested in taking better care of their pets fuels the growth of the companion animal specialty drugs market in this country. Brazil and Germany are two other countries that are expected to register considerable growth in the companion animal specialty drugs market during the forecast period.

Key Segments in the Companion Animal Specialty Drugs Market

By Product:

• Antibiotics
• Anti-Inflammatory Drugs
• Parasiticides
• Heartworm
• Behavioral Products
• Nutritional Products
• Anti-Obesity Drugs
• Skin Care Products
• Vaccines

Use promo code >> FMITODAY to get flat 20% discount

By Distribution Channel:

• Modern Trade
• Online Distribution
• Neighborhood Stores
• Other Retail Format

By Region:

• North America
• Latin America
• Asia Pacific
• MEA
• Europe

Top Related Reports:

General Anesthesia Drugs Market

Automated Suturing Devices Market

Digital Pathology Market

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

Browse All Reports: https://www.futuremarketinsights.com/reports

LinkedIn| Twitter| Blogs

The Saudi Arabia Pharmaceutical Market is expected to be worth US$ 5,209.5 million by the end of 2022, growing at a CAGR of 9.6% during the forecast period (2022–2032). Due to the country’s fast-growing population and significant influx of ex-pats, the pharmaceutical business in Saudi Arabia is anticipated to continue its high growth momentum. Pharmaceuticals supplied under a second brand name in association with regional businesses and distributors and manufactured by a number of international corporations dominate the Saudi pharmaceutical market.

The growth of Saudi Arabia’s pharmaceutical market is predicted to continue to propel over the estimation period owing to the country’s fast-rising population and large intake of expatriates.

The Saudi pharmaceutical business is dominated by branded pharmaceuticals produced by numerous global corporations and sold under a second brand name in collaboration with local firms and distributors.  Pharmaceutical demand is rapidly surging in Saudi Arabia attributed to the increase in the frequency of non-communicable illnesses and better healthcare infrastructure.

Get a Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gc-1733

Saudi Arabia imports around 80% of its medications from several other nations, and the country’s market is dominated by several global corporations. Surging lifestyle illnesses and high brand loyalty for multinational medications in Saudi Arabia are likely to bolster pharmaceutical demand throughout the predicted period. In addition to that, surging per capita income, expanding healthcare infrastructure, and increased penetration of health insurance firms in the Kingdom are fueling development in the Saudi pharmaceutical industry. In Saudi Arabia, MNCs dominate the pharmaceuticals market resulting in accounting for the lion’s share of the market.

The Saudi Arabia pharmaceutical market is anticipated to witness phenomenal growth due to rising health consciousness and increased healthcare spending is projected to bolster market expansion in the upcoming years. Macroeconomic reasons such as increased health insurance company penetration and healthcare reforms such as permitting 100% FDI in the pharmaceuticals industry are also expected to fuel market expansion. Several other significant developments in the marking include the fast-expanding number of religious visitors and the growing number of ex-pats in the nation. Saudi Arabia is known as the largest market in the GCC area that offers superior investment options for investors, which are driven by mandated insurance for ex-pats in the nation. These aforementioned factors are responsible for growth in the Saudi Arabia pharmaceutical market across the forecast period.

Inquire Before Buying Research Report: https://www.futuremarketinsights.com/ask-question/rep-gc-1733

Key Takeaways

• Saudi Arabia’s government and other multinational organizations are meticulously working towards improving their healthcare sector which is one of the key drivers to boost the growth of the Saudi Arabia pharmaceutical market throughout the forecast period. The Saudi Arabian General Investment Authority (SAGIA) and the British pharmaceutical company GlaxoSmithKline inked a manufacturing localization agreement in July 2019, (GSK). This is projected to help the latter accelerate its production capacity by 2022, producing a variety of Saudi-related employment.
• The dominant businesses actively participating in the Saudi Arabia pharmaceutical market are focusing on effective business tactics such as drug development collaborations and partnerships, R&D activities, and regional expansions, which are projected to enhance the Saudi Arabia pharmaceutical market growth.
• Owing to the rising prevalence of diabetes and cancer in both males and females among the Arab population is predicted to bolster the Saudi Arabia pharmaceuticals market throughout the forecast period. As per the projections of the World Health Organization (WHO), Saudi Arabia comprises the second-largest diabetes prevalence rate in the Middle East region and the seventh-highest diabetes prevalence rate in the world. It is analyzed that around 7 million individuals are diabetic, with an additional 3 million having pre-diabetes.

Competitive Landscape

Dominant market players are focusing on innovations that are driving the most recent advances in Saudi Arabia’s pharmaceutical sector. The country has managed to become one of the world’s top-rising economies on the basis of entrepreneurship and business.

Buy This Report: https://www.futuremarketinsights.com/checkout/1733

Key Companies Profiled:

• SPIMACO
• Tabuk Pharmaceuticals Manufacturing Co.
• Julphar
• Jamjoom Pharma
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Sanofi

Key Segments Covered in the Saudi Arabia Pharmaceutical Industry Analysis

Saudi Arabia Pharmaceutical Market by Product Type:

• Prescription Products
  • Branded Drugs
  • Generic Drugs
• Over The Counter (OTC) Products

Saudi Arabia Pharmaceutical Market by Disease Type:

• Cardiovascular Diseases
• Diabetes
• Cancer
• Obesity
• Infectious Diseases
• Other Diseases

Saudi Arabia Pharmaceutical Market by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies

Explore FMI’s Extensive ongoing Coverage in Healthcare Domain:

• https://www.xing.com/discover/detail-activities/6725503510.2067ba
• https://marketresearch00.blogs-service.com/47644756/parkinson-s-disease-market-is-projected-to-reach-a-market-size-of-us-17-12-billion-by-2033
• https://stemfemmes.mn.co/posts/parkinsons-disease-market-is-projected-to-reach-a-market-size-of-us-1712-billion-by-2033-33027144

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Wearable Medical Devices Market is predicted to reach US$ 73.48 billion in 2032, growing at a 28.1% CAGR. The wearable medical device market is anticipated to rise as a result of a growing population and an increase in chronic diseases. As a result of regulatory initiatives, the expansion of the healthcare industry, and an increase in the number of patients, businesses in the healthcare sector and product approvals have developed quickly.

A patient’s most likely diagnosis and treatments can be identified using 5G and AI. AI can also help healthcare providers predict which patients are anticipated to have complications after surgery to perform preventative actions. Learning in real-time with large amounts of data typically necessitates networks with high availability and high throughput.

With the advent of 5G networks, healthcare providers can use AI applications to provide immediate, high-quality care to patients worldwide. Therefore, cutting-edge advancements such as artificial intelligence and fifth-generation wireless networks are expected to impact wearable medical devices significantly.

Request a Sample of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-826

The wearable medical devices market is expanding. Individuals that typically purchase such items are those who are open to new experiences and ideas. The increasing number of early adopters and innovators in both developed and developing nations is anticipated to boost sales of wearable medical devices. The increasing demand for novel health monitoring techniques among athletes and fitness buffs is anticipated to propel the worldwide wearable medical devices market. An appreciable fraction of persons in the US and Canada are early adopters. So, the demand for wearable medical devices in North America is anticipated to expand at a higher rate.

Therapeutics, monitoring and diagnostics, foetal and obstetric monitoring, cardiovascular monitoring, and glucose monitoring are just a few of the many uses for wearable medical devices. In this category, therapeutic medical gadgets patients can wear are expected to dominate.

The FMI analysis predicts that by 2025, the market share of therapeutic medical devices that can be worn would exceed 50%. Among the many lifestyle-related conditions, lung problems, diabetes, and hearing loss contribute to this. During the evaluation phase, we don’t expect this tendency to reverse.

Improvements in both design and technology have boosted sales of wearable medical devices in recent years. However, adoption rates in the business continue to be challenged by several variables. The initial investment and ongoing upkeep of wearable technology might be costly for many people. Among other components, failure in sensors, batteries, and chips often necessitates frequent maintenance and repair, which slows consumer acceptance.

Contact our Market Research Specialist: https://www.futuremarketinsights.com/ask-question/rep-gb-826

Additionally, several nations do not supply enough medical wearable reimbursement options for their citizens. Because of this, sales of wearable medical devices are expected to stagnate in developed and developing nations.

Key Takeaways

• The wearable medical devices market is anticipated to reach a valuation of US$ 324.65 Billion by 2032.
• North America contributed for 38.1% of global revenue in 2020 because to rising rates of cardiovascular disease, diabetes, and cancer.
• Market growth is anticipated as a result of the increased use of wearable devices for health management during COVID-19.
• Rising prevalence of target diseases due to an ageing population and the need to minimise healthcare spending are driving the wearable medical device market.

Competitive Landscape

Although the wearable medical devices market is somewhat concentrated, a handful of industry giants control most sales. These businesses invest heavily in research and development of new items, followed by careful timing in releasing such products to the market.

Companies that now dominate the wearable medical devices market are focusing on diversifying their growth strategies, such as forging strategic partnerships, merging with other businesses, and expanding their product lines.

Recent Developments

• In April 2021, Alvalux Medical, a Belgian MedTech wearables manufacturer, announced that it had been granted a second patent by the United States Patent and Trademark Office for its new ocular insert device, which is intended to allow patients to treat retinal disorders at home through photo-biomodulation (PBM) therapy.
• As an additional comfort measure, 3M has announced the creation of a novel silicone adhesive material with conformable and breathable properties that is expected to be used in wearable medical devices with the goal of reducing the amount of skin that must be removed.
• In March of 2021, EOFlow, a provider of wearable drug delivery solutions, announced the release of a new smartphone application designed to be used in tandem with wearable insulin delivery devices.

Use promo code ->> FMITODAY to get a flat 20% discount

Wearable Medical Devices Market By Segmentation

By Product:

• Wearable Monitoring and Diagnostic Devices
• Fetal and Obstetric Devices
  • Wearable Fetal Monitors
  • Infant Motion Sensing Monitors
• Continuous Glucose Monitoring Devices
• Cardiac Monitoring Devices
  • Wearable Heart Rate Monitors
  • Wearable Pulse Oximeters
  • Wearable Blood Pressure Monitors
• Wearable Therapeutic Medical Device
• Hearing Aid
• Insulin Pump
• Respiratory Therapy Devices
  • Sleep Apnea Devices
  • Non-invasive Ventilation
• Health and Fitness Devices

By Application:

• Patient Monitoring
• Home Healthcare
• Health and Fitness

By Distribution Channel:

• Hospital Pharmacies
• Clinics
• Online Channels
• Hypermarkets

Explore FMI’s Extensive Ongoing Coverage on Healthcare Domain:

• https://www.xing.com/discover/detail-activities/6725503510.2067ba
• https://marketresearch00.blogs-service.com/47644756/parkinson-s-disease-market-is-projected-to-reach-a-market-size-of-us-17-12-billion-by-2033
• https://stemfemmes.mn.co/posts/parkinsons-disease-market-is-projected-to-reach-a-market-size-of-us-1712-billion-by-2033-33027144

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

The global Laboratory Information Systems (LIS) Market is expected to be worth US$ 1.8 billion by 2021. Sales are expected to increase at a 10.2% CAGR, bringing the market size to US$ 1.9 billion by 2022.

Sales are expected to grow at a healthy 10.2% CAGR over the assessment period, thanks to the aforementioned factors. Between 2022 and 2032, the overall demand for Laboratory Information Systems is expected to grow at a CAGR of 10.2%, totaling around US$ 4.2 million by 2032.

Massive technical improvements in the healthcare sector over time have included automation, big data analytics, and cloud computing. The necessity to balance administrative and caring activities is the most crucial feature of the sector. Thanks to the development of sophisticated laboratory testing technologies, this is now achievable.

Laboratories are the foundational stone for primary healthcare administration. It is the laboratories which are the site for drug development and API formulations. To accelerate the effectiveness of these functions, there is a need to streamline mundane operations such as data collation, assimilation, and record maintenance.

Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-875

The need for systematic data documentation to reduce paperwork is primarily driving the laboratory information systems market. Significant adoption has been witnessed since the COVID-19 pandemic’s onset, enabling healthcare providers to concentrate on drug and vaccine development by smoothening data collection procedures.

Key Findings

• Europe & North America will remain lucrative, accounting for 4/5^th of the revenue pie
• Cloud-based laboratory information systems to register maximum increase during the forecast period
• Vendors are increasingly capitalizing on developing LIS software for various healthcare verticals
• Hospital-grade laboratory information systems are gaining significant momentum

“Manufacturers are increasing their presence across emerging markets and forging effective distribution networks with regional players. This is helping them expand their outreach and broaden their customer base,” opines the FMI analyst.

Have a Conversation with the Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-875

Competitive Intelligence

The global laboratory information systems market is highly fragmented, characterized by the presence of over 50 vendors. Prominent players include: Cerner Corp., Evident, McKesson, Medical Information Technology (MEDITECH), Epic Systems Corporation, SCC Soft Computer, Roper Technologies Inc., CompuGroup Medical and LabWare.

With regard to product launches, Cerner Corporation launched CommunityWorks Foundations, a tailor-made cloud-based technology platform for rural and critical access hospitals in July 2020. This technology shall prove instrumental in reducing overhead costs and reducing lengthy implementation procedures. The platform enables hospitals to maintain electronic health records, reducing immense amount of paperwork.

Recently, in August 2020, Medical Information Technology (MEDITECH) partnered with TECHNATION Health in Canada. This collaboration is aimed at enhancing the privacy and security framework of healthcare providers across the nation, ensuring better patient data security. The solution involves the provision of cybersecurity and data sovereignty among other objectives.

Use promo code ->> FMITODAY to get a flat 20% discount

Key Segments Covered in the Laboratory Information Systems Industry Analysis

By Components:

• Software
• Hardware
• Services

By Delivery Mode:

• On Premise
• Cloud-Based

By End User:

• Hospitals
• Clinics
• Independent Laboratories
• Others

Have a Look at Related Research Reports in the Healthcare Domain:

• https://marketresearch01.fitnell.com/57250028/parkinson-s-disease-market-is-projected-to-reach-a-market-size-of-us-17-12-billion-by-2033
• https://blogs24.ka-blogs.com/70279431/parkinson-s-disease-market-is-projected-to-reach-a-market-size-of-us-17-12-billion-by-2033
• https://researchanalysis24.ambien-blog.com/22406135/parkinson-s-disease-market-is-projected-to-reach-a-market-size-of-us-17-12-billion-by-2033

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs